HomeNVV1 • FRA
add
Novavax Inc
Previous close
€8.33
Day range
€7.84 - €8.12
Year range
€3.33 - €23.93
Market cap
1.32B USD
Avg Volume
3.88K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 84.51M | -54.80% |
Operating expense | 66.95M | -37.70% |
Net income | -121.30M | 7.25% |
Net profit margin | -143.53 | -105.22% |
Earnings per share | -0.76 | 39.68% |
EBITDA | -117.12M | -2.46% |
Effective tax rate | 0.84% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 909.53M | 39.69% |
Total assets | 1.71B | 3.34% |
Total liabilities | 2.24B | -4.14% |
Total equity | -526.44M | — |
Shares outstanding | 160.18M | — |
Price to book | -2.53 | — |
Return on assets | -18.38% | — |
Return on capital | 150.12% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -121.30M | 7.25% |
Cash from operations | -144.81M | -265.18% |
Cash from investing | 31.91M | 273.52% |
Cash from financing | -97.00K | -100.05% |
Net change in cash | -106.97M | -172.07% |
Free cash flow | -78.48M | -210.04% |
About
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.
The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca. Wikipedia
Founded
1987
Headquarters
Website
Employees
1,543
